Abstract
Drug costs account for approximately 20% of the total cost of cancer care in the United States. High drug costs add to the economic burden to the health care system. The study aimed to systematically assess the cost-effectiveness evidence of Cyclin-Dependent Kinase (CDK) 4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer from a US societal/payer’s perspective.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
